ATG4D Protein
Overview
ATG4D (Autophagy-Related Protein 4D) is a cysteine protease that belongs to the ATG4 family of autophagy-regulating enzymes. Also known as APG4D or LC3-converter D, ATG4D is encoded by the ATG4D gene located on human chromosome 4q28.1. This protein functions as a key modulator of macroautophagy (hereafter referred to as autophagy), a fundamental cellular degradation pathway essential for maintaining cellular homeostasis and removing damaged organelles and protein aggregates. The ATG4 family comprises four members in mammals (ATG4A through ATG4D), with ATG4D representing a specialized autophagy regulator that has gained increasing attention in neurodegeneration research due to its role in clearing pathological protein inclusions characteristic of neurodegenerative diseases.
Function and Biology
ATG4D primarily functions as a protease with substrate specificity toward microtubule-associated protein 1 light chain 3 (LC3) and gamma-aminobutyric acid receptor-associated protein (GABARAP) family proteins. These LC3-like proteins are essential components of the autophagy machinery, serving as markers that allow the selective recognition and engulfment of cargo into autophagic vesicles called autophagosomes. ATG4D catalyzes two critical proteolytic reactions in the LC3 lipidation cycle. First, it processes the inactive pro-LC3 and pro-GABARAP precursors to expose their terminal glycine residues, generating the mature, cytosolic form (LC3-I or GABARAP-I). Second, and uniquely important, ATG4D functions as a delipidate enzyme that can cleave the phosphatidylethanolamine (PE) moiety conjugated to LC3 and GABARAP on the outer membrane of autophagosomes, a process known as delipidation. This recycling mechanism allows the regeneration of free LC3 and GABARAP proteins, preventing their depletion and maintaining the capacity for sustained autophagy during periods of cellular stress.
The catalytic activity of ATG4D depends on its catalytic cysteine residue (Cys74), which forms a thioester intermediate with the substrate. Unlike other ATG4 family members, ATG4D demonstrates distinct kinetic properties and substrate preferences, suggesting specialized functional roles in different cellular contexts and tissue types. ATG4D expression appears particularly enriched in neurons and other tissues with high metabolic demands.
Role in Neurodegeneration
ATG4D's involvement in neurodegeneration stems from autophagy's crucial role in clearing misfolded proteins and dysfunctional mitochondria, processes that become compromised in age-related neurodegenerative diseases. In Alzheimer's disease, the accumulation of amyloid-beta (Aβ) and hyperphosphorylated tau represents a pathological hallmark, and impaired autophagy contributes to their accumulation. In Parkinson's disease, alpha-synuclein aggregates similarly depend on autophagy for clearance. Reduced ATG4D expression or activity could contribute to the accumulation of these protein aggregates by limiting the recycling capacity of the autophagy machinery. Additionally, dysfunctional mitophagy (selective autophagy of mitochondria), which requires proper LC3 and GABARAP processing by ATG4D, may exacerbate the mitochondrial dysfunction and neuroinflammation characteristic of neurodegeneration.
Molecular Mechanisms
ATG4D modulates autophagy flux through its dual enzymatic activities. The processing function ensures continuous availability of functional LC3 and GABARAP molecules required for autophagosome biogenesis. The delipidation function prevents the permanent sequestration of these proteins in the autophagosomal membrane, maintaining cellular pools of the LC3-like proteins. During neurodegeneration, impaired ATG4D activity could result in reduced autophagy capacity, accumulation of dysfunctional autophagosomes, and increased cellular stress. Conversely, enhanced ATG4D activity might augment autophagy flux and protein aggregate clearance.
Clinical and Research Significance
ATG4D represents a promising therapeutic target for neurodegenerative disease intervention. Strategies to enhance ATG4D expression or activity could potentially accelerate the clearance of pathological protein aggregates and dysfunctional organelles. Research is ongoing to characterize ATG4D dysfunction in various neurodegenerative contexts and to develop selective ATG4D modulators as neuroprotective agents.
ATG4A, ATG4B, ATG4C, LC3, GABARAP, autophagy, macroautophagy, mitophagy, amyloid-beta, tau, alpha-synuclein, protein aggregation, Alzheimer's disease, Parkinson's disease